Mode
Text Size
Log in / Sign up
N/A N=114 Randomized Health Services Research

Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV

Mild Cognitive Impairment

Enrolled (actual)
114
Serious AEs
0.0%
Results posted
Oct 2018
Primary outcome: Primary: Geriatric Depression Scale — 2.6; 2.1; 2.8; 1.9 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
APOE genotype and Alzheimer's disease risk disclosure (Behavioral); Alzheimer's disease risk disclosure (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Brigham and Women's Hospital
Primary completion
Jul 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Geriatric Depression Scale
2.6; 2.1; 2.8; 1.9; 2.1; 2.0
PRIMARY
Mini State Trait Anxiety Inventory
36.3; 36.5; 39.0; 36.6; 36.2; 36.2
SECONDARY
Impact of Event Scale (IES)
8.2; 8.1; 13.1; 11.5; 12.5; 12.4
SECONDARY
Psychological Impact of Test Disclosure (IGT-AD)
24.7; 19.5; 24.1; 20.3
SECONDARY
Recall and Comprehension of Risk Information
0.8; 1.2; 1.0; 1.2
SECONDARY
Participant Satisfaction
6.0; 6.1; 5.9; 6.2; 5.5; 6.0
SECONDARY
User Ratings of Risk Assessment Experience
3.5; 3.6; 3.0; 3.5
SECONDARY
Health Behavior and Insurance Changes
6; 17; 16; 26; 7; 15
SECONDARY
Insurance and Advance Planning Changes
2; 1; 0; 1; 0; 0
SECONDARY
Participation in Alzheimer's Disease-related Research After Receiving the Alzheimer's Disease Risk Estimate.
0; 6; 2; 10

Summary

This study is intended to examine the impact of receiving a genetic risk assessment for Alzheimer's disease (AD) among individuals with Mild Cognitive Impairment (MCI).

Eligibility Criteria

Inclusion Criteria

  • Individuals (55-90 years old) with Mild Cognitive Impairment (amnestic-MCI as defined by the Petersen criteria)
  • Individuals who have a close friend, relative or spouse (18+) willing to be a study partner. Study partners attend each study visit with the participant and also complete surveys and interviews.

Exclusion Criteria

  • Individuals with current, untreated anxiety or depression
  • Individuals who do not meet the criteria for amnestic-MCI
  • Individuals who have the diagnosis of dementia or Alzheimer's disease
  • Individuals not fluent in English
  • Individuals who do not have a study partner
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01434667). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search